FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study

Core Insights - Azenta, Inc. is participating in the FinnGen project, a significant research initiative in personalized medicine in Finland, which involves genomic and health data from 500,000 Finnish biobank participants [1][3] - The company will provide proteomics profiling for up to 20,000 individuals using Olink's advanced technology, highlighting its commitment to healthcare innovation [1][2] - The collaboration aims to enhance understanding of disease mechanisms, identify new biomarkers, and develop targeted treatments [2][3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering a range of services including cold-chain sample management and multiomics services for drug development and clinical research [4] - The company operates globally with a presence in North America, Europe, and Asia, supporting pharmaceutical, biotech, academic, and healthcare institutions [4] Project Significance - The FinnGen project is notable for its public-private partnership approach, aiming to create a world-class resource for future studies in personalized medicine [3] - The integration of proteomics with genomic data is expected to provide novel insights into health and disease, facilitating breakthroughs in prevention, diagnosis, and treatment [2][3]